3rd Quarter - Report

COVIDIEN LP for COVIDIEN LP

Firm
Client
Income
—
Expenses
$430,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

9 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

S. 506 -Stop Tax Haven Abuse Act; H.R. 1265- Stop Tax Haven Abuse Act; Administration FY 2010 Budget Request; International tax on foreign direct investment.

Foreign entity interest: As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.

LobbyistCovered position, as disclosed
SUSAN KATHLEEN BUNNING —
JONATHAN S COLLARD —
WHITNEY GARDINER —

Contacted: SENATE; White House Office; Office of Science & Technology Policy (OSTP); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: S. 506 (111th), H.R. 1265 (111th)

Financial Institutions/Investments/Securities FIN

Financial Regulatory Reform - issues relating to derivatives.

Foreign entity interest: As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.

LobbyistCovered position, as disclosed
WHITNEY GARDINER —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); SENATE; Office of Science & Technology Policy (OSTP); White House Office

Copyright/Patent/Trademark CPT

S. 515/H.R.1260- Patent Reform Act of 2009.

Foreign entity interest: As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.

LobbyistCovered position, as disclosed
JONATHAN S COLLARD —
WHITNEY GARDINER —

Contacted: Health & Human Services, Dept of (HHS); White House Office; SENATE; Office of Science & Technology Policy (OSTP); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA)

Bills named: S. 515 (111th), H.R. 1260 (111th)

Health Issues HCR

General issues related to healthcare, healthcare reimbursement, and healthcare reform; S. 1213 - Patient Centered Outcomes Research Act; H.R. 2502- Comparative Effectiveness Research Act of 2009; S. 1142 -Informed Health Care Decision Making Act. Senate Finance Committee Healthcare Reform Proposal-medical device tax; Tri-Committee Healthcare Reform Proposal; (H.R. 3200, America's Affordable Health Choice Act of 2009) S. 440/H.R.1346- Medical Device Safety Act of 2009; H.R. 2976/S. 1312- Medicare Safe Needles Disposal Coverage Act of 2009; S.1679 Affordable Health Choice Act.

Foreign entity interest: As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.

LobbyistCovered position, as disclosed
SUSAN KATHLEEN BUNNING —
JONATHAN S COLLARD —
WHITNEY GARDINER —
JOHN CHRISTOPHER KALAVRITINOS —

Contacted: Office of Science & Technology Policy (OSTP); SENATE; White House Office; HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS)

Bills named: S. 440 (111th), S. 1142 (111th), S. 1213 (111th), H.R. 3200 (111th), H.R. 1346 (111th), H.R. 2976 (111th), H.R. 2502 (111th), S. 1312 (111th), S. 1679 (111th)

Medicare/Medicaid MMM

Issues related to bariatric surgery; comparative effectiveness; S. 301- Physicians Payments Sunshine Act.

Foreign entity interest: As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.

LobbyistCovered position, as disclosed
SUSAN KATHLEEN BUNNING —
JONATHAN S COLLARD —
WHITNEY GARDINER —
JOHN CHRISTOPHER KALAVRITINOS —

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE; Office of Science & Technology Policy (OSTP); White House Office

Bills named: S. 301 (111th)

Budget/Appropriations BUD

H.R.1105- Fiscal 2009 Omnibus appropriations; S. Con Res 13; H.Con Res 85; H.R. 1, American Recovery and Reinvestment Act of 2009; H.R. 2346/ S.1054- Supplemental Appropriations Act (issues relating to pandemic flu); Fiscal 2010 Financial Serves Approps.

Foreign entity interest: As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.

LobbyistCovered position, as disclosed
SUSAN KATHLEEN BUNNING —
JONATHAN S COLLARD —
WHITNEY GARDINER —
JOHN CHRISTOPHER KALAVRITINOS —

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Office of Science & Technology Policy (OSTP); SENATE; White House Office

Bills named: S. 1054 (111th), H.R. 2346 (111th), H.Con.Res. 85 (111th), H.R. 1 (111th), H.R. 1105 (111th), S.Con.Res. 13 (111th)

Energy/Nuclear ENG

HEU/LEU related issues for nuclear medicine. H.R. 3276 American Medical Isotopes Production Act of 2009

Foreign entity interest: As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.

LobbyistCovered position, as disclosed
SUSAN KATHLEEN BUNNING —
JONATHAN S COLLARD —
JOHN CHRISTOPHER KALAVRITINOS —

Contacted: HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); White House Office; Office of Science & Technology Policy (OSTP); SENATE; Health & Human Services, Dept of (HHS)

Bills named: H.R. 3276 (111th)

Labor Issues/Antitrust/Workplace LBR

S.560/H.R. 1409 - Employee Free Choice Act.

Foreign entity interest: As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.

LobbyistCovered position, as disclosed
SUSAN KATHLEEN BUNNING —
WHITNEY GARDINER —

Contacted: White House Office; SENATE; Food & Drug Administration (FDA); Office of Science & Technology Policy (OSTP); HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: H.R. 1409 (111th), S. 560 (111th)

Pharmacy PHA

Issues related to controlled substances, pain and addiction drugs generally.

Foreign entity interest: As the parent, Covidien PLC (as disclosed on the LD1) has an interest in the issues listed above.

LobbyistCovered position, as disclosed
SUSAN KATHLEEN BUNNING —
JONATHAN S COLLARD —
WHITNEY GARDINER —
JOHN CHRISTOPHER KALAVRITINOS —

Contacted: SENATE; Office of Science & Technology Policy (OSTP); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); White House Office; Health & Human Services, Dept of (HHS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.